HistoSonics, a leading developer of non-invasive histotripsy therapy platforms, has announced the completion of a $102 million Series D financing round, significantly oversubscribed and led by Alpha Wave Ventures. The round saw participation from new investors, including Amzak Health and HealthQuest Capital, along with existing backers such as Johnson & Johnson Innovation - JJDC, and Lumira Ventures.
The funds will be utilized to accelerate advancements in HistoSonics' Edison Histotripsy System, support commercial growth in the US and global markets, and initiate the BOOMBOX Master Study, which will evaluate the Edison System for liver tumor treatment. The Edison System, granted FDA De Novo clearance in 2023, uses a novel, non-invasive form of focused ultrasound to mechanically destroy and liquefy liver tumors without damaging surrounding healthy tissue.
HistoSonics, headquartered in Ann Arbor, Michigan, and Minneapolis, Minnesota, is pioneering a new category of non-invasive medicine with its histotripsy technology, which offers a promising alternative to traditional treatments like surgery, radiation, and chemotherapy. The company's proprietary platform enables precise, real-time visualization and control during tumor treatment, providing significant patient benefits, including quicker recovery times. The Series D financing reflects strong investor confidence in HistoSonics' mission to transform the treatment landscape for liver tumors and other challenging clinical conditions.
